Sanofi/$SNY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sanofi
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Ticker
$SNY
Sector
Primary listing
Employees
82,878
Headquarters
Website
Sanofi Metrics
BasicAdvanced
$122B
5.81
$8.52
0.44
$1.60
3.23%
Price and volume
Market cap
$122B
Beta
0.44
52-week high
$60.12
52-week low
$44.62
Average daily volume
3.5M
Dividend rate
$1.60
Financial strength
Current ratio
1.274
Quick ratio
0.542
Long term debt to equity
20.951
Total debt to equity
31.709
Dividend payout ratio (TTM)
52.29%
Interest coverage (TTM)
16.91%
Profitability
EBITDA (TTM)
14,023.577
Gross margin (TTM)
71.34%
Net profit margin (TTM)
19.95%
Operating margin (TTM)
20.73%
Effective tax rate (TTM)
19.24%
Revenue per employee (TTM)
$638,380
Management effectiveness
Return on assets (TTM)
4.65%
Return on equity (TTM)
9.00%
Valuation
Price to earnings (TTM)
5.81
Price to revenue (TTM)
1.156
Price to book
1.51
Price to tangible book (TTM)
6.08
Price to free cash flow (TTM)
6.293
Free cash flow yield (TTM)
15.89%
Free cash flow per share (TTM)
7.869
Dividend yield (TTM)
3.23%
Forward dividend yield
3.23%
Growth
Revenue change (TTM)
15.65%
Earnings per share change (TTM)
117.96%
3-year revenue growth (CAGR)
2.85%
10-year revenue growth (CAGR)
3.35%
3-year earnings per share growth (CAGR)
11.66%
10-year earnings per share growth (CAGR)
7.20%
3-year dividend per share growth (CAGR)
5.59%
10-year dividend per share growth (CAGR)
3.24%
What the Analysts think about Sanofi
Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Bulls say / Bears say
Sanofi raised its annual sales growth outlook to a high single-digit percentage, citing strong global demand for Dupixent, and confirmed its guidance for low double-digit earnings growth.
In Q1 2025, Sanofi’s business operating income climbed 20.1% to €2.90 billion, beating analyst estimates thanks to a 20.3% increase in Dupixent sales and 54.9% growth in its newborn respiratory treatment Beyfortus.
Sanofi agreed to acquire Blueprint Medicines for up to $9.5 billion, strengthening its rare immunology portfolio with Ayvakit and boosting its pipeline with candidates such as elenestinib and BLU-808.
Sanofi’s shares dropped more than 9% in September 2025 after Phase III trial results for its experimental inflammation drug amlitelimab fell short compared to Dupixent, increasing worries about the company's pipeline after Dupixent's patent expires in 2031.
Even with strong Dupixent sales, Sanofi’s business operating income in Q2 2025, excluding one-time items, rose only 3.3% to €2.46 billion, missing analyst expectations and signaling margin pressures from higher profit-sharing and R&D expenses.
Possible U.S. sector tariffs and ongoing national security probes into pharmaceutical imports could drive up Sanofi’s production costs and disrupt supplies to its largest market.
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Sanofi Financial Performance
Revenues and expenses
Sanofi Earnings Performance
Company profitability
Sanofi News
AllArticlesVideos
Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance
WSJ19 hours ago
Sanofi's quarterly profit boosted by Dupixent and newer drugs, forecast unchanged
Reuters20 hours ago
QuantHealth Secures Strategic Investment from Sanofi Ventures to Accelerate AI-Driven Clinical Trials
Business Wire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sanofi stock?
Sanofi (SNY) has a market cap of $122B as of October 25, 2025.
What is the P/E ratio for Sanofi stock?
The price to earnings (P/E) ratio for Sanofi (SNY) stock is 5.81 as of October 25, 2025.
Does Sanofi stock pay dividends?
Yes, the Sanofi (SNY) stock pays dividends to shareholders. As of October 25, 2025, the dividend rate is $1.59864 and the yield is 3.23%. Sanofi has a payout ratio of 52.29% on a trailing twelve-month basis.
When is the next Sanofi dividend payment date?
The next Sanofi (SNY) dividend payment date is unconfirmed.
What is the beta indicator for Sanofi?
Sanofi (SNY) has a beta rating of 0.44. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.